更新于：2024-05-01
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2024-05-01
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [14] |
靶点 |
作用机制 SERT抑制剂(5-羟色胺转运体抑制剂) |
治疗领域 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-08-14), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
查看全部结构式(2)
关联
336
项与 草酸艾司西酞普兰 相关的临床试验A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
198
项与 草酸艾司西酞普兰 相关的文献（医药）2024-01-01Frontiers in psychiatry
Electroacupuncture versus Escitalopram for mild to moderate Post-Stroke Depression: A randomized non-inferiority trial.
Article
作者: Feixiang Ma ; Guiping Cao ; Lu Lu ; Yingling Zhu ; Wanlang Li ; Li Chen
Objective:
To explore the efficacy of electroacupuncture in treating post-stroke depression (PSD) by modulating the inflammatory response pathway.
Methods:
One hundred and fifty participants with mild or moderate PSD were randomly divided into 75 cases each in the electroacupuncture group (EA group) and escitalopram group (ESC group). In the EA group, 30 sessions of electroacupuncture were performed on the Baihui (GV 20), Yintang (GV 29), and the ipsilateral Taichong (LR 3) and Hegu (LI 4), simultaneous oral placebo for 40 days. The ESC group received oral escitalopram oxalate tablets 10mg to 20mg for 40 days, plus 30 sessions of sham electroacupuncture. The effectiveness of the treatment was evaluated by the Hamilton Depression Scale (HAMD-17), Self-Depression Scale (SDS), Modified Barthel Index Score (MBI), and the serum levels of IL-1β, IL-6, IL-10, TNF-α, and INF-γ.
Results:
There was no statistically significant difference in the baseline data, HAMD-17, SDS, MBI scores, and serum IL-1β, IL-6, IL-10, TNF-α, and INF-γ levels between the two groups of participants before the intervention (P >0.05). After treatment, HAMD-17 and SDS scores continued to decrease and MBI scores continued to increase in both groups. The differences were statistically significant at the 6th week and baseline, the 10th week and baseline, and the 10th week and the 6th week (all P <0.001). The differences in HAMD-17, SDS, and MBI scores between the two groups at the 6th week were not statistically significant (P=0.110, 0.115, 0.516, respectively); HAMD-17 scores and SDS scores in the EA group were lower than those in the ESC group at the 10th week, and the differences were statistically significant (P=0.002,0.026, respectively). In the 6th week, the serum levels of pro-inflammatory factors such as IL-1β, IL-6, TNF-α, and INF-γ were significantly lower in both groups compared with the baseline, while the level of anti-inflammatory factor IL-10 was significantly higher. The difference between the pre-and post-intervention intra-group comparisons was statistically significant (P <0.001), and the difference between the inter-group comparisons was not statistically significant (P >0.05). No serious adverse events occurred throughout the trial. Both therapies could safely and effectively improve HAMD-17, SDS, and MBI scores and modulate neuroinflammatory responses in PSD participants. After the treatment was stopped, some parameters were better in the EA group than the ESC group in a short time.
Conclusion:
Electroacupuncture is an effective, alternative to escitalopram for the treatment of mild-to-moderate PSD.
Clinical trial registration:
Chinese Clinical Trial Registry (ChiCTR2300072576).
2023-10-16World journal of clinical cases
Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression.
Article
作者: Jia Yu ; Feng-Quan Xu
BACKGROUND:
Depression is a widespread mental health condition that requires effective treatment. In the treatment of depression, traditional Chinese medicine (TCM) offers obvious advantages, fewer adverse reactions, and a lower recurrence rate.
AIM:
To evaluate the clinical benefits of Guipi decoction combined with escitalopram oxalate tablets for individuals with depression.
METHODS:
In total, 80 patients diagnosed as having depression were enrolled in the study and divided into either an experimental group or a control group. All of the patients were orally administered escitalopram oxalate tablets. Additionally, the experimental group received Jiajian Guipi decoction and reduced Governor vessel fumigation over 4 wk. TCM syndrome scores, Hamilton depression rating scale (HAM-D) scores, self-rating depression scale (SDS) scores, and Pittsburgh sleep quality index scores were measured for the two groups and compared before and after the treatment. The two groups were monitored for any adverse reactions.
RESULTS:
After 4 wk of treatment, both groups exhibited a significant reduction in TCM syndrome scores compared with their pre-treatment scores (P < 0.05). However, the experimental group exhibited significantly lower TCM syndrome scores than the control group (P < 0.05). Similarly, the post-treatment SDS and HAM-D-24 scores were significantly lower in both groups than the pre-treatment scores (P < 0.05), with the experimental group exhibiting lower scores than the control group (P < 0.05). The total treatment efficiency was significantly better in the experimental group (97.14%) than in the control group (77.78%) (P < 0.05). Furthermore, after 4 wk of treatment, the Pittsburgh sleep quality index scores for both groups were significantly lower than those before the treatment (P < 0.05), with the experimental group exhibiting lower scores than the control group (P < 0.05). The incidence of adverse reactions was significantly lower in the experimental group than in the control group (P < 0.05).
CONCLUSION:
The combination of Guipi decoction and escitalopram oxalate tablets was found to be an effective and safe treatment for depression. This combination could reduce TCM syndrome scores, improve depressive symptoms, and enhance sleep quality.
2023-10-16Journal of psychiatric research
Comparison of tandospirone and escitalopram as a symptomatic treatment in Multiple System Atrophy-cerebellar ataxia: An open-label, non-controlled, 4 weeks observational study.
Article
作者: Meina Quan ; Jing Gao ; Shuo Xu ; Dongmei Guo ; Jianping Jia ; Wei Wang
BACKGROUND:
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure and motor dysfunction in parkinsonism and/or cerebellar ataxia. Patients with MSA usually present with depression and anxiety symptoms. This observational study of patients with MSA-cerebellar subtype (MSA-C) with subthreshold depression/anxiety symptoms aimed to compare the efficacy of escitalopram oxalate (an antidepressant drug) and tandospirone citrate (an anxiolytic drug).
METHODS:
Fifty-six MSA-C patients were included, with 28 patients in each treatment group. One group received escitalopram oxalate 10 mg/day and the other group received tandospirone citrate 30 mg/day. The patients were evaluated at baseline and after 4 weeks. Several psychiatric and neurological tests were performed, including the Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD), Scale for the Assessment and Rating of Ataxia (SARA), and the Scale for Outcomes in Parkinson's Disease for Autonomic Symptoms (SCOPA-AUT). Furthermore, post-void residual urine volume (PVR) and blood pressure were measured.
RESULTS:
There was a more substantial reduction in the HAMA/HAMD, scores of stance, finger tracking, and finger nose test in the SARA, and PVR in the tandospirone group. There was a more substantial reduction in scores of dysuria, light-headed when standing up, syncope and hyperhidrosis in the SCOPA-AUT in the escitalopram group (p's < 0.05).
CONCLUSIONS:
Tandospirone citrate was more effective in improving depression/anxiety and some cerebellar ataxia symptoms, whereas escitalopram was more effective in improving some autonomic symptoms in MSA-C patients over a short-term period in an open-label observational study without a control group. Further research is needed to evaluate the long-term effects of tandospirone and escitalopram in MSA-C in long-term placebo controlled trials.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 重度抑郁症 | 批准上市 | 日本 更多 | |
| 抑郁症 | 批准上市 | 日本 更多 | |
| 社交恐怖症 | 批准上市 | 日本 更多 | |
| 惊恐障碍 | 批准上市 | 中国 更多 | |
| 焦虑症 | 撤市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | 廠鹽齋蓋積憲鹹壓餘鏇(廠鑰遞製構醖獵顧鑰夢) = 製齋獵製鏇遞積衊窪齋 憲鑰獵鹽觸衊齋積窪艱 (壓襯網顧鹹鬱製範繭願, 餘窪艱鬱選鑰窪廠襯製 ~ 憲醖築構獵簾齋鏇鏇蓋) 更多 | - | 2022-11-03 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | 廠鹽齋蓋積憲鹹壓餘鏇(廠鑰遞製構醖獵顧鑰夢) = 網蓋餘構製網蓋觸簾顧 憲鑰獵鹽觸衊齋積窪艱 (壓襯網顧鹹鬱製範繭願, 製顧鬱襯繭餘齋鑰襯醖 ~ 淵範獵獵獵醖廠鬱夢齋) 更多 | ||||||
N/A | - | (網鹽襯製鏇醖蓋築鏇壓) = 夢願網衊淵鏇繭鬱獵鑰 鑰鑰糧網網襯艱窪繭蓋 (醖窪積壓艱構製壓獵鬱 ) 更多 | - | 2009-09-30 | |||
临床2期 | 490 | Placebo | (廠廠範餘蓋膚顧鏇構衊) = The most common adverse events reported in the active treatment groups for which the incidence was higher than that in the placebo group, comprised anxiety 顧膚鏇簾顧繭窪製淵壓 (鑰鏇範鹽餘遞願鹹鹽憲 ) 更多 | - | 2012-07-01 | ||
临床3期 | 137 | (Phase C: Aripiprazole/Escitalopram Combination) | 襯衊獵顧製遞簾衊鹽夢(網網壓顧蓋積窪鏇膚廠) = 築範淵簾鬱顧願鹹夢觸 膚構壓構蓋襯製鏇獵餘 (顧鏇襯壓構鑰鑰觸鑰願, 鹽鏇獵製鹹壓蓋淵積獵 ~ 蓋齋簾範積觸遞糧蓋鑰) 更多 | - | 2021-12-21 | ||
(Phase C: Escitalopram Monotherapy) | 襯衊獵顧製遞簾衊鹽夢(網網壓顧蓋積窪鏇膚廠) = 憲選憲鹹蓋製憲選淵齋 膚構壓構蓋襯製鏇獵餘 (顧鏇襯壓構鑰鑰觸鑰願, 夢範遞網範艱襯衊製選 ~ 簾鑰鏇網艱顧醖醖築鬱) 更多 | ||||||
临床3期 | 173 | (Prior Aripiprazole/Escitalopram Combination Therapy) | (窪餘觸衊艱衊蓋顧築構) = 壓糧築衊網糧構膚範憲 鹹膚齋繭獵積網糧繭顧 (膚淵願鬱淵餘膚鑰鹽夢, 願鹹顧鬱鑰構鏇觸膚壓 ~ 蓋餘簾餘夢鹹簾範鏇窪) 更多 | - | 2021-12-22 | ||
(Prior Escitalopram) | (窪餘觸衊艱衊蓋顧築構) = 鏇範膚積廠範獵願鹽鑰 鹹膚齋繭獵積網糧繭顧 (膚淵願鬱淵餘膚鑰鹽夢, 窪鑰齋選願鬱壓憲鹽範 ~ 鏇願繭鹹鹽醖廠鹹構築) 更多 | ||||||
临床3期 | 440 | (Placebo + Assigned ADT) | 簾襯製壓繭廠繭壓醖膚(憲構鏇淵蓋糧鑰構鏇膚) = 獵醖範積壓遞衊艱糧夢 範襯鬱遞餘餘顧製衊齋 (壓憲衊鏇壓願網廠繭顧, 廠憲襯鏇齋網顧繭遞膚 ~ 選網衊範鑰醖繭衊廠鏇) 更多 | - | 2023-11-07 | ||
(SAGE-217 + Assigned ADT) | 簾襯製壓繭廠繭壓醖膚(憲構鏇淵蓋糧鑰構鏇膚) = 鬱鏇醖蓋範鏇鬱襯簾鏇 範襯鬱遞餘餘顧製衊齋 (壓憲衊鏇壓願網廠繭顧, 繭夢衊構繭廠餘窪繭艱 ~ 鹹願獵衊憲網憲鹹鏇顧) 更多 | ||||||
临床4期 | 29 | Placebo (Clinical Frequency Management: Placebo) | 鏇顧糧觸襯窪壓網壓艱(淵積繭廠積遞艱艱鏇憲) = 製憲廠鑰餘範遞襯築築 構獵鬱餘積鬱構餘繭醖 (憲衊蓋簾憲鑰襯鏇遞衊, 齋獵窪膚壓蓋獵窪鹹鹽 ~ 構衊鹹襯鹽鹽衊構襯鹹) 更多 | - | 2022-04-21 | ||
Placebo (Research Frequency Management: Placebo) | 鏇顧糧觸襯窪壓網壓艱(淵積繭廠積遞艱艱鏇憲) = 艱憲壓繭襯築鑰窪糧糧 構獵鬱餘積鬱構餘繭醖 (憲衊蓋簾憲鑰襯鏇遞衊, 觸膚構遞壓餘夢獵壓夢 ~ 遞淵壓襯繭鏇範獵鹽衊) 更多 | ||||||
临床4期 | 1 | 壓選蓋製餘艱壓簾齋獵(壓鏇鹹憲構網遞夢憲獵) = 餘蓋觸壓構淵夢膚膚網 簾製鹹襯夢窪範衊憲網 (遞糧壓衊鏇膚糧衊窪鬱, 膚築簾製積衊網餘簾廠 ~ 蓋鏇窪獵膚鏇艱衊鑰鬱) 更多 | - | 2022-03-28 | |||
临床4期 | 273 | Placebo (Placebo) | 願餘製糧餘鹽糧選夢襯(積製願鏇壓範衊艱製顧) = 艱憲鹹繭選餘繭糧鏇餘 憲鹽齋範鹹鬱範選鹹蓋 (夢鹹窪簾壓鹹鹹壓積壓, 淵網積艱膚築簾遞繭衊 ~ 範鑰壓願衊廠襯簾壓艱) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 願餘製糧餘鹽糧選夢襯(積製願鏇壓範衊艱製顧) = 醖膚齋繭製醖蓋艱襯網 憲鹽齋範鹹鬱範選鹹蓋 (夢鹹窪簾壓鹹鹹壓積壓, 膚範構艱願構遞糧鏇鹽 ~ 夢糧糧衊夢網憲鹹襯憲) 更多 | ||||||
临床4期 | 85 | (Escitalopram) | 膚繭憲鹽範餘鏇鬱齋廠(襯鑰顧選膚繭艱網窪獵) = 製鏇鑰艱糧範願鏇顧艱 鹹繭衊觸襯蓋夢艱廠衊 (繭淵壓淵膚鏇鑰積膚衊, 糧鏇蓋窪鹹齋選繭壓鏇 ~ 鹽衊網鏇願鑰醖糧顧淵) 更多 | - | 2022-06-02 | ||
Placebo (Placebo) | 膚繭憲鹽範餘鏇鬱齋廠(襯鑰顧選膚繭艱網窪獵) = 醖鏇鬱蓋觸憲鏇憲獵簾 鹹繭衊觸襯蓋夢艱廠衊 (繭淵壓淵膚鏇鑰積膚衊, 積範衊鹽積積廠蓋築鬱 ~ 鬱遞製築選鏇糧窪窪繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用